U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H15NO2S
Molecular Weight 273.35
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MODAFINIL, (S)-

SMILES

NC(=O)C[S@+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=YFGHCGITMMYXAQ-IBGZPJMESA-N
InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H15NO2S
Molecular Weight 273.35
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22537794

(+)-modafinil is an enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. (+)-enantiomer of modafinil was clarified to be S-configuration. The optical enantiomers of modafinil have similar pharmacological actions. Both modafinil enantiomers bind in vitro to the dopamine transporter and inhibit dopamine reuptake with the R- slightly more potent than the S-enantiomer. As a component of racemic mixture (+)-modafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
48.62 µM [IC50]
8.7 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROVIGIL

Approved Use

PROVIGIL (1:1 racemic mixture of S- and R-modafinil enantiomers) is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder.

Launch Date

1998
PubMed

PubMed

TitleDatePubMed
An enantioselective assay for (+/-)-modafinil.
2001 Aug
Crystal and molecular structure of an (S)-(+)-enantiomer of modafinil, a novel wake-promoting agent.
2004 Oct
R-modafinil attenuates nicotine-taking and nicotine-seeking behavior in alcohol-preferring rats.
2015 Jun
Patents

Sample Use Guides

The recommended dose of PROVIGIL (1:1 racemic mixture of S- and R-modafinil enantiomers) is 200 mg given once a day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:27:45 GMT 2025
Edited
by admin
on Mon Mar 31 23:27:45 GMT 2025
Record UNII
152JRG3T0U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MODAFINIL, (S)-
Common Name English
CRL 40983
Preferred Name English
MODAFINIL, (+)-
Common Name English
CRL-40983
Code English
2-((S)-(DIPHENYLMETHYL)SULFINYL)ACETAMIDE
Systematic Name English
NH-02D
Code English
(+)-MODAFINIL
Systematic Name English
(S)-(+)-MODAFINIL
Common Name English
NH 02D
Code English
ACETAMIDE, 2-((S)-(DIPHENYLMETHYL)SULFINYL)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID70457709
Created by admin on Mon Mar 31 23:27:45 GMT 2025 , Edited by admin on Mon Mar 31 23:27:45 GMT 2025
PRIMARY
PUBCHEM
11173366
Created by admin on Mon Mar 31 23:27:45 GMT 2025 , Edited by admin on Mon Mar 31 23:27:45 GMT 2025
PRIMARY
RS_ITEM_NUM
1445415
Created by admin on Mon Mar 31 23:27:45 GMT 2025 , Edited by admin on Mon Mar 31 23:27:45 GMT 2025
PRIMARY
CHEBI
77591
Created by admin on Mon Mar 31 23:27:45 GMT 2025 , Edited by admin on Mon Mar 31 23:27:45 GMT 2025
PRIMARY
CAS
112111-47-4
Created by admin on Mon Mar 31 23:27:45 GMT 2025 , Edited by admin on Mon Mar 31 23:27:45 GMT 2025
PRIMARY
SMS_ID
300000042598
Created by admin on Mon Mar 31 23:27:45 GMT 2025 , Edited by admin on Mon Mar 31 23:27:45 GMT 2025
PRIMARY
FDA UNII
152JRG3T0U
Created by admin on Mon Mar 31 23:27:45 GMT 2025 , Edited by admin on Mon Mar 31 23:27:45 GMT 2025
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER